Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
08 Aprile 2024 - 10:30PM
Cellectis Announces Two Poster Presentations on Novel TALEN®
Editing Process for Gene Correction and Gene Insertion in HSPCs at
the ASGCT Annual Meeting
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that preliminary data exploring novel
TALEN® editing process in hematopoietic stem and progenitor cells
(HSPCs) will be presented at the American Society of Gene and Cell
Therapy (ASGCT) 27th Annual Meeting, to be held in Baltimore,
Maryland, on May 7-11, 2024.
Poster presentations:
Title: Circularization of Non-Viral Single-Strand DNA
Template for Gene Correction and Gene Insertion Improves Editing
Outcomes in HSPCs
Presenter: Alex Boyne, Gene Editing Platform
Manager at CellectisSession Date/Time: May 9, 2024
at 12PM ETSession Title: Nonviral Therapeutic Gene
Delivery and Synthetic/Molecular ConjugatesPresentation
Room: Exhibit HallFinal Abstract Number:
1235
Cellectis presents the development of a novel
gene editing process, leveraging the TALEN® technology and
non-viral DNA template delivery, enabling highly efficient gene
correction and gene insertion in hematopoietic stem and progenitor
cells (HSPCs).
Title: Intron Editing
of HSPC Enables Lineage-Specific Expression of
Therapeutics
Presenter: Julien Valton, Ph.D., Vice President
Gene Therapy at CellectisSession Date/Time: May 5,
2024 at 12PM ET Session Title: Gene Targeting and
Gene Correction New TechnologiesPresentation Room:
Exhibit HallFinal Abstract Number: 721
Gene therapy using hematopoietic and progenitor
stem cells (HSPC) has the potential to provide a lifelong supply of
genetically encoded therapeutics. Gene editing strategies enabling
supra-endogenous expression of therapeutics often rely on
constitutive promoters resulting in transgene overexpression
irrespective of cellular differentiation, which could be
detrimental for HSPC function. Cellectis presents the development
of a TALEN® mediated promoter-less intron editing strategy that
relies on the endogenous cellular RNA splicing machinery to induce
lineage-specific transgene expression exclusively after HSPC
differentiation.
Full abstracts and presentations will be available on Cellectis’
website following the
event:https://www.cellectis.com/en/investors/scientific-presentations/
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
24 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statement
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as “has
the potential,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements include statements about the potential of our R&D
programs. These forward-looking statements are made in light of
information currently available to us and are subject to numerous
risks and uncertainties, including with respect to the numerous
risks associated with biopharmaceutical product candidate
development. Furthermore, many other important factors, including
those described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2022 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media
contacts:
Pascalyne Wilson, Director, Communications, +33
(0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7
76 77 46 93, media@cellectis.com
Investor Relation contact:
Ashley R. Robinson, LifeSci Advisors, +1 617 430
7577
- ASGCT 2024-curtain raiser
Grafico Azioni Cellectis Nom Eo 05 (TG:ZVA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Cellectis Nom Eo 05 (TG:ZVA)
Storico
Da Set 2023 a Set 2024